Insulin degludec

Long‑acting Insulin AnalogRx: PrescriptionCompound: Approved

Also known as: IDeg, Insulin degludec, NN1250, Ryzodeg (combination), Tresiba, Ultra‑long insulin, Xultophy (combination)

Educational Only — Not medical advice. Consult a qualified clinician before using any peptide.

Source Insulin degludec at Peptiology

Save 10% with code PEPTI-BOSSRABBIT-10

Shop Now & Save 10% →

Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.

Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.

Summary

Insulin degludec is a long‑acting basal insulin analogue prescribed for once‑daily subcutaneous injection in adults with type 1 or type 2 diabetes. It provides stable, low‑fluctuation glucose‑lowering over 24 hours, facilitating flexible dosing and reducing the need for multiple injections.

Mechanism of Action

Degludec binds the insulin receptor on muscle and adipose cells, activating the receptor’s tyrosine kinase cascade. This promotes GLUT‑4 translocation, increasing glucose uptake, and suppresses hepatic gluconeogenesis, thereby lowering blood glucose. Its molecular modifications create multi‑hexamer formation after injection, prolonging absorption and extending action for up to 42 hours.

What the Research Shows

Randomised trials (ONWARDS 3) showed degludec achieved a mean HbA1c reduction to 7.2% after 26 weeks, comparable to the once‑weekly insulin icodec, which lowered HbA1c to 7.0% and had a higher rate of level 2/3 hypoglycaemia. A network meta‑analysis of 44 RCTs (23,699 participants) found no significant difference in HbA1c reduction between degludec and other basal insulins, but degludec (both 100 U/mL and 200 U/mL) lowered odds of overall, nocturnal and severe hypoglycaemia versus NPH. Comparative substudies of tirzepatide versus degludec demonstrated that tirzepatide produced greater reductions in liver fat, visceral adipose tissue and body weight, indicating degludec’s modest impact on these secondary outcomes.

Reported Benefits

Clinical evidence indicates degludec provides effective basal glucose control comparable to other basal insulins, with a low risk of overall and nocturnal hypoglycaemia relative to NPH. Its ultra‑long duration allows flexible dosing times and reduces injection frequency compared with twice‑daily basal regimens.

Limitations of the Evidence

Degludec does not consistently outperform other basal analogues in HbA1c reduction, and weight gain is similar to other insulins. Comparative data suggest it is less effective than tirzepatide for reducing liver fat and body weight. Long‑term real‑world safety beyond trial periods remains under‑studied.

Safety Considerations

Trials report low rates of severe hypoglycaemia, though hypoglycaemia still occurs, especially if dosing is mismatched to meals. Weight gain is modest but comparable to other basal insulins. No specific adverse events were detailed in the cited abstracts; standard insulin precautions (e.g., injection‑site reactions) apply.

How It Is Administered

Insulin degludec is administered subcutaneously once daily, using pre‑filled pens or vials. It is available in 100 U/mL and 200 U/mL formulations, allowing dose titration to individual glucose targets.

Routes of Administration

Subcutaneous

Goals & Uses

  • Cardiovascular safety in diabetesCardiovascularHigh
  • HbA1c reductionGlycemic ManagementHigh
  • Reduction of nocturnal hypoglycemiaSafety / TolerabilityHigh
  • Glycemic control in type 2 diabetesMetabolicHigh
  • Glycemic control in type 1 diabetesMetabolic / EndocrineHigh
  • Flexible dosing schedulePatient AdherenceModerate
  • Reduced nocturnal hypoglycaemiaSafetyHigh

Contraindications

  • Hypoglycemia (during active episode)MetabolicHigh
  • HypoglycaemiaMetabolicHigh
  • Hypersensitivity to insulin degludec or excipientsImmunologicHigh
  • Diabetic ketoacidosis (DKA)MetabolicHigh

Adverse Effects

  • HypokalemiaElectrolyteUncommon
  • HypoglycemiaMetabolicCommonAbnormally low blood glucose
  • Peripheral edemaFluid BalanceUncommonSwelling of the arms or legs
  • Allergic reactionsImmunologicalRare
  • Injection site reactionsLocalCommon
  • Allergic/anaphylactic reactionsImmunologicalRare
  • Injection‑site reactionsLocalUncommon
  • HypoglycaemiaMetabolicCommon
  • Weight gainMetabolicCommonIncrease in body weight
  • LipodystrophyDermatologicRare

Drug Interactions

  • Thiazolidinediones (e.g., pioglitazone)Moderate
  • Beta‑blockersModerate
  • Beta-blockersModerate
  • Antidiabetic agents (oral/injectable)Moderate
  • AlcoholModerate
  • CorticosteroidsModerate
  • Fluoroquinolone antibioticsModerate
  • Other insulins or insulin secretagoguesModerate

Population Constraints

  • PregnancyReproductive SafetyRelative
  • Hepatic impairmentOrgan FunctionRelative
  • Renal impairmentOrgan ImpairmentRelative
  • Severe renal impairmentOrgan ImpairmentRelative
  • Children <1 yearPediatricAbsolute
  • Elderly patientsAgeRelative
  • Severe hepatic impairmentOrgan ImpairmentRelative
  • Pediatric patients < 1 yearAgeAbsolute

Regulatory Status

  • European UnionApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusEMA approval 2015.
  • United StatesApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusFDA approved 2015; marketed as Tresiba.
  • United KingdomApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusMHRA approval aligned with EU.

FDA approved (2015); EMA approved (2015); UK MHRA approved. Marketed as Tresiba. No generic version available as of 2024.

Evidence & Sources

Frequently Asked Questions

How does insulin degludec differ from other basal insulins?

Degludec forms multi‑hexamers after injection, creating a depot that releases insulin slowly over up to 42 hours. This provides a flatter glucose‑lowering profile and lower nocturnal hypoglycaemia risk compared with NPH and some other basal analogues.

Can degludec be taken at any time of day?

Yes. Clinical trials allow flexible dosing times because its long action maintains basal coverage even if the injection time varies day to day, as long as the interval between doses remains roughly 24 hours.

Is insulin degludec suitable for insulin‑naïve patients?

The ONWARDS 3 trial enrolled insulin‑naïve adults with type 2 diabetes and demonstrated that degludec safely reduced HbA1c to 7.2% with low hypoglycaemia rates, supporting its use as an initial basal insulin.

How does the risk of hypoglycaemia with degludec compare to other treatments?

Network meta‑analysis showed degludec has significantly lower odds of overall, nocturnal and severe hypoglycaemia than NPH. In the ONWARDS 3 head‑to‑head study, degludec had fewer level 2/3 hypoglycaemic events than the once‑weekly insulin icodec.

Does insulin degludec help with weight loss?

Evidence indicates degludec does not produce meaningful weight loss; weight change is comparable to other basal insulins. In contrast, tirzepatide showed greater reductions in body weight and liver fat when directly compared with degludec.

What is Insulin degludec?

Insulin degludec is a long‑acting basal insulin analogue prescribed for once‑daily subcutaneous injection in adults with type 1 or type 2 diabetes. It provides stable, low‑fluctuation glucose‑lowering over 24 hours, facilitating flexible dosing and reducing the need for multiple injections.

What is Insulin degludec used for?

Insulin degludec is educationally associated with: Cardiovascular safety in diabetes, HbA1c reduction, Reduction of nocturnal hypoglycemia, Glycemic control in type 2 diabetes, Glycemic control in type 1 diabetes, Flexible dosing schedule, Reduced nocturnal hypoglycaemia. Educational only — not medical advice.

How is Insulin degludec administered?

Recorded routes of administration: Subcutaneous.

What are the potential side effects of Insulin degludec?

Reported adverse effects include: Hypokalemia, Hypoglycemia, Peripheral edema, Allergic reactions, Injection site reactions, Allergic/anaphylactic reactions, Injection‑site reactions, Hypoglycaemia, Weight gain, Lipodystrophy. This list is not exhaustive — consult a qualified clinician.

Who should avoid Insulin degludec?

Recorded contraindications: Hypoglycemia (during active episode), Hypoglycaemia, Hypersensitivity to insulin degludec or excipients, Diabetic ketoacidosis (DKA). Consult a qualified clinician before use.

More Insulin Analogues

See all Insulin Analogues →

Browse All PeptidesBuild My Stack